Therapeutic Advances in Musculoskeletal Disease

Papers
(The TQCC of Therapeutic Advances in Musculoskeletal Disease is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Successful treatment of severe COVID-19 pneumonia, a case series with simultaneous interleukin-1 and interleukin-6 blockade with 1-month follow-up118
Regenerative medicine for early osteoarthritis61
Comparison of the efficacy and risk of discontinuation between non-TNF-targeted treatment and a second TNF inhibitor in patients with rheumatoid arthritis after first TNF inhibitor failure34
Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study33
Actigraphy-derived physical activity levels and circadian rhythm parameters in patients with psoriatic arthritis: relationship with disease activity, mood, age and BMI27
The impact of psoriatic arthritis on quality of life: a systematic review24
Anti-sclerostin antibodies: a new frontier in fragility fractures treatment24
Poor health and functioning in patients with axial spondyloarthritis during the COVID-19 pandemic and lockdown: REUMAVID study (phase 1)23
Early Osteoarthritis Questionnaire (EOAQ): a tool to assess knee osteoarthritis at initial stage22
To flare or not to flare: patients’ and rheumatologists’ perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis22
Efficacy and retention rate of secukinumab in psoriatic arthritis across different clinical phenotypes: insights from the Italian GISEA Registry20
Erratum to “Clinical effectiveness of symptomatic therapy compared with standard step-up care for the treatment of low-impact psoriatic oligoarthritis: the two-arm parallel group randomised POISE feas20
Mechanisms hypothesized for pain-relieving effects of exercise in fibromyalgia: a scoping review19
Is there wastage in the research resources for ankylosing spondylitis? An analysis of clinical trial discontinuation and nonpublication outcome18
Bone marrow edema in children: chronic nonbacterial osteomyelitis and its mimickers18
Utilising a non-surgical intervention in the knee osteoarthritis care pathway: a 6-year retrospective audit on NHS patients17
Risk of ischaemic stroke among new users of glucosamine and chondroitin sulphate: a nested case–control study17
Open questions on the management of targeted therapies for the treatment of systemic sclerosis-interstitial lung disease: results of a EUSTAR survey based on a systemic literature review17
MRI lesions in SpA: a comparison with noninflammatory back pain using propensity score adjustment method16
Validation of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in ANA-positive Chinese patients16
Dispositional traits help explain individual differences in relationships between a radiographic knee osteoarthritis measure, pain, and physical function16
Systemic sclerosis associated interstitial lung disease: a survey of current practices in France16
The socioeconomic status of patients with ankylosing spondylitis and its association with the burden of the disease and permanent disability: a cross-sectional cluster analysis15
Drug switching in axial spondyloarthritis patients in Germany – a social listening analysis15
Back pain treatment: a new perspective14
A novel infrapatellar approach of ultrasound-guided intra-articular injection of the knee from both lateral and medial side: a case series14
Safety and efficacy of SHR4640 combined with febuxostat for primary hyperuricemia: a multicenter, randomized, double-blind, phase II study14
Acute effects of exercise on pain symptoms, clinical inflammatory markers and inflammatory cytokines in people with rheumatoid arthritis: a systematic literature review13
Major adverse cardiovascular events or venous thromboembolism in patients with rheumatoid arthritis initiating biological or targeted synthetic disease-modifying antirheumatic drugs: a nationwide, pop13
Fracture in clinical studies of tofacitinib in rheumatoid arthritis13
An oleuropein-based dietary supplement may improve joint functional capacity in older people with high knee joint pain: findings from a multicentre-RCT and post hoc analysis13
Association between baseline cardiovascular risk and incidence rates of major adverse cardiovascular events and malignancies in patients with psoriatic arthritis and psoriasis receiving tofacitinib13
Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance13
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)13
Counting the costs: a nationwide study on healthcare use following an adalimumab biosimilar switch in >1300 inflammatory arthritis patients12
The role of antifibrotics in the treatment of rheumatoid arthritis–associated interstitial lung disease12
Comparable long-term retention rates and effects on bone mineral density of denosumab treatment in patients with osteoporosis with or without autoimmune inflammatory rheumatic diseases: real-life data12
Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus12
Normal C-reactive protein in active psoriatic arthritis: results from real-world clinical practice12
An update on the use of conventional and biological disease-modifying anti-rheumatic drugs in hand osteoarthritis12
Potential complementary and/or synergistic effects of curcumin and boswellic acids for management of osteoarthritis11
Retraction notice11
Risk factors associated with the occurrence of total knee arthroplasty in patients with knee osteoarthritis: a nested case–control study11
Infections in psoriatic arthritis: association with treatment10
SCORE2 is superior to SCORE in predicting the presence of carotid plaques and intima-media thickness in rheumatoid arthritis patients: a cross-sectional study using carotid ultrasound10
Thanks to Reviewers10
Early-stage hypertension defined by the 2017 ACC/AHA blood pressure guideline carries excessive cardiovascular risk in axial spondyloarthritis patients10
Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review10
Predictive model to identify multiple failure to biological therapy in patients with rheumatoid arthritis10
Imaging in psoriatic arthritis: established methods and emerging techniques9
Achievement of more stringent disease control is associated with reduced burden on workplace and household productivity: results from long-term certolizumab pegol treatment in patients with psoriatic 9
The effect of ixekizumab on axial manifestations in patients with psoriatic arthritis from two phase III clinical trials: SPIRIT-P1 and SPIRIT-P29
Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol9
New insights on multigenic autoinflammatory diseases9
The protocol of a clinical effectiveness trial comparing standard step-up care, early combination DMARD therapy and early use of TNF inhibitors for the treatment of moderate to severe psoriatic arthri9
Incidence rate of and risk factors for glomerulonephritis in patients with axial spondyloarthritis: a nationwide population-based study9
Switching from rituximab originator to GP2013 or CT-P10 biosimilars in autoimmune rheumatic diseases: drug retention rate and safety data from a multicentric retrospective cohort9
0.098484992980957